WebDoctor Encyclopedia

Article

R-CHOP Chemotherapy

What is R-CHOP?

R-CHOP is a combination chemotherapy regimen that is the most widely used first treatment for diffuse large B-cell lymphoma, the most common type of aggressive non-Hodgkin lymphoma. The name comes from the first letters of its five medicines:

Letter Medicine Type
R Rituximab Monoclonal antibody against CD20
C Cyclophosphamide Alkylating chemotherapy
H Hydroxydaunorubicin (doxorubicin) Anthracycline chemotherapy
O Oncovin (vincristine) Vinca alkaloid chemotherapy
P Prednisolone (or prednisone) Steroid

R-CHOP is usually given in cycles every 21 days, most often for six cycles. Four of the medicines are given into a vein on the first day of each cycle, and prednisolone is taken as tablets for five days. For many people with diffuse large B-cell lymphoma, R-CHOP is curative: it can get rid of the lymphoma permanently.

A brief history

CHOP chemotherapy was developed in the 1970s and remained the standard treatment for aggressive lymphoma for over two decades. Several more intensive regimens were tested in the 1980s and 1990s, but none proved better. The big breakthrough came with rituximab, the first antibody approved for cancer treatment, in 1997. Adding rituximab to CHOP improved survival so clearly that R-CHOP became the new standard in the early 2000s.

1. Key facts at a glance

Feature Details
Type of treatment Chemotherapy combined with an antibody (chemoimmunotherapy)
Main use Diffuse large B-cell lymphoma and other CD20-positive aggressive B-cell lymphomas
How it is given Drip into a vein on day 1 plus steroid tablets for 5 days
Cycle length 21 days (sometimes 14 days)
Usual course 6 cycles, about 4-5 months; fewer for early-stage disease
Where Day unit; most people go home the same day
Main side effects Low blood counts, infection, hair loss, nausea, tiredness, tingling fingers

2. How it works

Medicine How it acts
Rituximab Binds the CD20 protein on B cells, marking them for destruction by the immune system and triggering cell death
Cyclophosphamide Damages DNA by cross-linking its strands
Doxorubicin Slots into DNA and blocks the enzyme topoisomerase II
Vincristine Stops the cell’s internal scaffolding (microtubules) from forming, halting cell division
Prednisolone Directly kills lymphoma cells and reduces inflammation and nausea

Each medicine attacks lymphoma cells in a different way. Combining them makes it harder for the lymphoma to resist treatment, while spreading out the side effects so that no single drug needs to be given at a toxic dose.

Why rituximab made a difference

Most B-cell lymphomas carry CD20 on their surface. Rituximab targets this protein, so its effects are focused on B cells, both healthy and cancerous. Healthy B cells regrow from stem cells, which do not carry CD20, over the months after treatment ends. Adding rituximab improved results without greatly increasing side effects.

3. Who it is for

Conditions treated

Condition Role of R-CHOP
Diffuse large B-cell lymphoma Standard first treatment for most people
Primary mediastinal large B-cell lymphoma One option; more intensive regimens are often preferred
Follicular lymphoma When treatment is needed, especially if transformation is suspected
Primary bone lymphoma Usually followed by radiotherapy in some cases
Primary thyroid lymphoma Large B-cell types
Intravascular large B-cell lymphoma Standard backbone, often with central nervous system protection
Primary cutaneous B-cell lymphomas Leg-type large B-cell lymphoma
Mantle cell lymphoma Part of some treatment plans, often with other drugs

Who may need adjustments

Situation Possible change
Older or frailer people (over about 80) Reduced doses (R-mini-CHOP)
Heart problems Doxorubicin may be replaced or the dose reduced
Nerve damage or diabetes Vincristine dose may be reduced
Risk of brain involvement Extra treatment to protect the central nervous system
Hepatitis B infection Antiviral medicine to prevent reactivation

The lymphoma’s biology

Not all diffuse large B-cell lymphomas behave the same way. Tests on the biopsy can show the cell of origin (germinal centre or activated B-cell type) and whether there are rearrangements of the MYC, BCL2 or BCL6 genes. Lymphomas with both MYC and BCL2 rearrangements, sometimes called double-hit lymphomas, tend to be more aggressive and may be treated with more intensive regimens instead of R-CHOP.

Protecting the brain and spinal cord

A small number of people with diffuse large B-cell lymphoma are at higher risk of the lymphoma spreading to the brain or spinal cord. Risk is higher with involvement of certain sites, such as the kidneys, adrenal glands or testes. For these people, doctors may add high-dose methotrexate or check the spinal fluid. Your team will explain whether this applies to you.

4. Before treatment

Step Why it is done
Biopsy Confirms the type of lymphoma
PET-CT scan Shows where the lymphoma is (staging)
Blood tests Blood counts, kidney and liver function, LDH
Hepatitis B, C and HIV tests Rituximab can reactivate hepatitis B
Heart scan Doxorubicin can affect the heart
Bone marrow test or lumbar puncture In some people, to check spread
Fertility discussion Sperm storage or egg preservation may be possible
Central line Sometimes inserted for easier drips

5. What to expect: step by step

Step What happens
1. Pre-treatment check Blood tests a day or two before each cycle
2. Day 1 Anti-sickness medicine and paracetamol/antihistamine, then rituximab followed by the three chemotherapy drugs
3. Days 1-5 Prednisolone tablets at home
4. Days 7-14 Blood counts at their lowest; highest infection risk
5. Days 15-21 Counts recover
6. Next cycle Repeated every 21 days
7. Interim scan Often a PET-CT after 2-4 cycles
8. End-of-treatment scan PET-CT to check response

The first rituximab infusion

The first rituximab dose is given slowly, over several hours, because reactions such as fever, chills and shivering are most common at this point. Later infusions can be given more quickly, and some centres use an injection under the skin from the second cycle onwards. The whole first treatment day can take most of a day.

Interim scans

Many centres repeat the PET-CT scan partway through treatment. A good early response is reassuring. If the scan shows that lymphoma is still active, your team may discuss changing the plan, adding radiotherapy or taking another biopsy.

6. Side effects and risks

Side effect Cause Notes
Low white cells and infection Chemotherapy Growth factor injections may be given
Infusion reactions Rituximab Fever, chills, rash; mostly first dose
Hair loss Doxorubicin, cyclophosphamide Usually complete; grows back after treatment
Nausea and vomiting Chemotherapy Well controlled with modern medicines
Tingling or numbness in hands and feet Vincristine Report it; dose may be reduced
Constipation Vincristine Laxatives help
Mouth sores Doxorubicin Mouthwashes and good oral care
High blood sugar, mood changes, sleep problems Prednisolone Short-lived
Red urine Doxorubicin Harmless colour change for a day or two
Heart damage Doxorubicin Rare at standard doses; risk rises with total dose
Hepatitis B reactivation Rituximab Prevented with antiviral medicine
Infertility Cyclophosphamide Risk depends on age and dose

Infection warning signs

Fever of 38 degrees C or higher, shivering or feeling suddenly unwell during chemotherapy can signal neutropenic sepsis, a medical emergency. Call the hospital’s 24-hour helpline straight away, even at night.

7. Results and outlook

Study Main finding
GELA trial, people aged 60-80 (399 people) Adding rituximab to CHOP raised the complete response rate from 63% to 76% and improved survival, without clinically important extra toxicity (Coiffier et al., 2002)
MInT trial, younger good-prognosis patients (824 people) Three-year event-free survival was 79% with rituximab versus 59% without, and overall survival was 93% versus 84% (Pfreundschuh et al., 2006)
POLARIX (879 people) Replacing vincristine with polatuzumab vedotin (pola-R-CHP) modestly improved progression-free survival compared with R-CHOP, with similar overall survival at 2 years (Tilly et al., 2022)

Overall, about 6 or 7 in 10 people with diffuse large B-cell lymphoma are cured with R-CHOP-based treatment. Outcomes depend on factors such as age, stage, LDH level, fitness and the lymphoma’s biology.

8. Recovery and aftercare

During treatment

Tip Why
Check your temperature if unwell Early treatment of infection is vital
Avoid people with infections Especially in the week after each cycle
Eat small, frequent meals Helps with nausea and taste changes
Stay active Gentle exercise reduces tiredness
Use laxatives as advised Prevents vincristine constipation
Avoid live vaccines They can be harmful during treatment

After treatment

Area What to expect
Energy Tiredness can last several months
Hair Usually starts regrowing within a few months
Nerve symptoms Often improve slowly; may persist in some people
Immune recovery B cells take 6-12 months to return
Follow-up Clinic visits every few months for the first 2 years
Long-term checks Heart health, second cancers and fertility

Coping with hair loss

Hair loss usually starts two to three weeks after the first cycle. Some people cut their hair short beforehand, while others choose wigs, scarves or hats. Scalp cooling is not usually used with R-CHOP. Eyebrows and eyelashes may thin too, and everything typically regrows within a few months of finishing treatment, sometimes with a different texture or colour at first.

Fertility

Cyclophosphamide can affect fertility, although many younger people treated with R-CHOP go on to have children. Men can usually store sperm before starting. Options for women are more limited because treatment often needs to begin quickly, but they should be discussed.

Food and drink

Steroids can increase appetite and raise blood sugar, while chemotherapy may change taste. Eating little and often, choosing foods you enjoy and drinking plenty of fluids can help. Your team may give advice on food hygiene when your blood counts are low.

Returning to normal life

Many people return to work, study and hobbies within a few months of finishing treatment. Recovery is gradual, and it is normal to feel emotionally drained even when the lymphoma has gone. Support groups and lymphoma charities offer advice for life after treatment.

If lymphoma returns or does not respond

Some people need further treatment. Options may include different chemotherapy followed by an autologous stem cell transplant, CAR-T cell therapy, bispecific antibodies or other new drugs. Many people are still cured with second-line treatment.

9. Alternatives

Alternative When it is considered
Pola-R-CHP Some people with intermediate or high-risk diffuse large B-cell lymphoma
More intensive regimens (such as DA-EPOCH-R) Some high-grade or mediastinal lymphomas
R-mini-CHOP People over about 80
Radiotherapy Added for bulky or localised disease
Clinical trials New combinations and antibodies

10. Frequently asked questions

Question Answer
Will I lose my hair? Usually yes; it grows back after treatment
Can I work during treatment? Some people can, especially in the second half of each cycle
Is R-CHOP given in hospital? Usually in a day unit; overnight stays are uncommon
Why is my urine red? Doxorubicin colours urine red for a day or two; it is harmless
Can I drink alcohol? Small amounts are usually fine; check with your team
Will I need radiotherapy too? Sometimes, for bulky or early-stage disease
Can I have vaccines? Inactivated vaccines such as flu are usually advised; avoid live vaccines
How will I know if it worked? A PET-CT scan at the end of treatment

11. Questions to ask your care team

  • What type and stage of lymphoma do I have?
  • How many cycles of R-CHOP will I need?
  • What is the aim: cure or control?
  • Will I need radiotherapy or treatment to protect the brain?
  • What should I do if I get a fever?
  • How might treatment affect my fertility?
  • What happens if the lymphoma does not respond?

Resources

  1. Coiffier, B. et al. (2002) ‘CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma’, New England Journal of Medicine, 346(4), pp. 235-242.
  2. Pfreundschuh, M. et al. (2006) ‘CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group’, The Lancet Oncology, 7(5), pp. 379-391.
  3. Tilly, H. et al. (2022) ‘Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma’, New England Journal of Medicine, 386(4), pp. 351-363.
  4. National Cancer Institute (2026) Aggressive B-Cell Non-Hodgkin Lymphoma Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/lymphoma/hp/aggressive-b-cell-lymphoma-treatment-pdq (Accessed: October 2026).
  5. National Cancer Institute (2026) R-CHOP. Available at: https://www.cancer.gov/about-cancer/treatment/drugs/r-chop (Accessed: October 2026).

Prepared by the editorial team, October 2026.